Overexpression of the ErbB2 receptor tyrosine kinase in breast cancer contributes to tumor development and is associated with poor prognosis. However, the mechanism by which ErbB2 might contribute to metastasis is not well defined. To identify genes that mediate ErbB2-driven cell motility, we performed differential gene expression analysis of ErbB2-expressing migrating breast cancer cells vs mutant ErbB2-expressing non-migrating cells. Among the genes that were specifically induced in migrating cells were known transcriptional targets of ErbB2, such as matrix metalloproteinases, and novel ErbB2 targets. Contribution of selected candidate genes to ErbB2-driven cell motility was tested by small interfering RNA targeting. Knockdown of the soluble form of ST2 (sST2), also called interleukin-1 receptor-like 1, one of the most robustly induced genes, decreased ErbB2-induced cell motility in two different cell lines. In response to ErbB2 activation, sST2 protein expression and secretion were increased. Moreover, recombinant sST2 associated with the plasma membrane and sST2-blocking antibodies reduced ErbB2-induced motility. Interestingly, cells from metastatic breast tumors secreted higher levels of sST2 than primary tumor cells. Finally, sST2 was found at high levels in the serum of metastatic breast cancer patients. Our data suggest that sST2 contributes to breast cancer cell motility and that sST2 secretion is associated with metastasis.
Introduction
The ErbB2/HER2/Neu receptor tyrosine kinase is abnormally expressed in close to 25% of breast cancer patients (Slamon et al., 1989) . Overexpression of ErbB2 correlates to aggressive forms of breast cancer with high metastatic risk and poor prognosis (Slamon et al., 1987) . ErbB2 has become a major therapeutic target in breast cancer (Slamon et al., 2001; Marty et al., 2005) . Its role in cell proliferation and tumor development is largely documented (Olayioye et al., 2000) , and several lines of evidence support a role in tumor cell metastasis. Transgenic mice overexpressing ErbB2 specifically in the mammary epithelium develop breast tumors and pulmonary metastases (Guy et al., 1992) . Moreover, overexpression of ErbB2 in mammary and pulmonary cell lines increases their metastatic potential in xenograft models (Dankort et al., 2001; Kedrin et al., 2009) . In vitro experiments also indicate that ErbB2 promotes cell motility and invasion, two key steps of the metastatic process (Hijazi et al., 2000; Spencer et al., 2000; Mazumdar et al., 2001; Marone et al., 2004) .
ErbB2 belongs to the ErbB family of transmembrane receptors, which includes ErbB1/EGFR (epidermal growth factor receptor), ErbB3 and ErbB4. ErbB2 has no identified ligands. However, ErbB2 overexpression or ligand-binding to another ErbB family member leads to ErbB2 homo-or heterodimerization, resulting in the activation of the kinase, leading to cell proliferation, survival and motility (Yarden and Sliwkowski, 2001 ). Many signaling cellular pathways contribute to ErbB2-induced cell motility including the Ras/mitogen-activated protein kinase, phosphatidylinositol 3 kinase/Akt, Memo/mDia1, SHP2 and FAK-dependent signaling (Yarden and Sliwkowski, 2001; Benlimame et al., 2005; Zaoui et al., 2008; Grossmann et al., 2009) . Interestingly, most of these pathways also activate gene transcription. Moreover, some studies have directly involved transcription factors, such as AP1, Fra1, NFAT or Cutl1 in the regulation of cell motility (Kustikova et al., 1998; Jauliac et al., 2002; Vial et al., 2003; Michl et al., 2005) .
We have studied the transcriptional program associated with ErbB2-induced breast cancer cell migration, and identified soluble ST2 (sST2) protein as a target of ErbB2, which contributes to cell motility and whose expression in clinical samples is associated with metastasis.
Results

ErbB2-driven migration is dependent on gene transcription
Loss of ErbB2 expression at the plasma membrane or expression of a mutant ErbB2 receptor lacking tyrosine autophosphorylation sites inhibits heregulin (HRG)-induced cell migration (Spencer et al., 2000; Marone et al., 2004) . We produced T47D-derived cell lines in which the native ErbB2 protein was substituted with either wild-type Neu-the rat counterpart of ErbB2-to produce the Neu cell lines (Neu1 and Neu2), or mutant Neu lacking the five major autophosphorylation sites to produce the NYPD cell lines (NYPD1 and NYPD2) (Marone et al., 2004) . We measured the ability of these cell lines to migrate in response to HRG in Boyden-like chambers. Migration of NYPD cells in response to HRG was strongly decreased relative to Neu cells ( Figure 1a ). Of note, basal migration of NYPD cells was not significantly lower than the basal migration of Neu cells (Figure 1a ). NYPD cell proliferation (Figure 1b ), survival and adhesion (data not shown) in response to HRG were not altered, probably due to the fact that the mutant NYPD receptor, through transactivation of ErbB3/4, is still able to trigger major signaling pathways, including the Ras/mitogen-activated protein kinase and the phosphatidylinositol 3 kinase/Akt pathways, to the same extent than the control receptor (Supplementary Figure S1 and (Marone et al., 2004) ).
Upon addition of HRG, NYPD cells went through early stages of cell motility such as cell polarization and formation of lamellipodia (Marone et al., 2004) , and migration of Neu and NYPD cells was not different at early times (Supplementary Figure S2) . These results suggested that the defect in migration of NYPD cells occurred at later stages of the migration process. We thus studied whether this defect might be associated with abnormal transcription of motility-associated genes. DRB, an inhibitor of RNA polymerase IIdependent transcription, abrogated the migratory advantage that HRG-challenged Neu cells had over NYPD cells (Figure 1c ). In contrast, DRB did not affect ErbB2-dependent NYPD cell migration (Figure 1c) . Similar results were obtained with cycloheximide, an inhibitor of translation (data not shown). These results indicated that HRG induced de novo messenger RNA (mRNA) and protein synthesis required for optimal migration of Neu cells and that this transcriptional program is defective in NYPD cells.
A genetic program associated with ErbB2-driven migration We have shown that the response of Neu and NYPD cells to HRG is different in terms of migration and largely dependent on transcription. We postulated that differential transcriptome analysis of the Neu and NYPD cells might reveal genes associated with ErbB2-dependent migration. mRNAs were collected from Neu and NYPD cells exposed to HRG in Boyden-like chambers for 0, 2, 4, 6 and 24 h. mRNAs were retrotranscribed and analyzed by whole-genome DNA microarrays. Figure 2a shows a hierarchical clustering of the gene expression pattern of Neu and NYPD cells exposed to HRG. The gene expression patterns of Neu and NYPD cells were different and segregated in two distinct branches of the dendrogram. This suggested that during ErbB2-induced migration, Neu and NYPD cells expressed distinct sets of genes. Of note, the expression patterns of Neu and NYPD cells no longer segregated at 24 h. sST2 in breast tumor cell motility and metastasis J Gillibert-Duplantier et al
We wanted to identify genes that are most likely involved in ErbB2-dependent cell motility. Such genes were defined by comparable expression in Neu and NYPD cells before HRG treatment (to exclude differences that might have been acquired by the cells during the selection process) and by increased expression in Neu cells, but not in NYPD cells, upon HRG treatment. Fold change (FC) analysis identified 200 probe sets whose expression was modified during HRG-induced migration differentially between Neu and NYPD cells, including 172 probe sets upregulated in Neu cells (vs NYPD cells) . Among these probe sets, the one coding for matrix metalloproteinase-1 (MMP1) was the most highly upregulated. MMP1 mRNA was rapidly increased, reached a maximum FC equal to 31 at 6 h and returned to basal at 24 h (Figure 2b ). Thus, because MMP1 is a demonstrated ErbB2 target gene (Bosc et al., 2001) , we searched for genes with an expression profile similar to that of MMP1 across all 20 samples. We identified 52 probe sets, representing 39 genes (Supplementary Table S3 ), whose expression strongly correlated with MMP1 expression (correlation factor X0.8).
We selected 12 of these genes for further validation. They included genes coding for receptors: integrin b6, coagulation factor-2 receptor-like 1 (F2RL1) and interleukin-1 receptor-like 1 (IL1RL1/ST2); MMPs: MMP-1 and MMP-10; signaling molecules: FGF-binding protein-1, Cdc42 effector protein 3 and dual specificity phosphatase 6; and proteins associated with vesicle transport: Rab31 and synaptogamin-like 2. Most of these genes are not known ErbB2 targets. We thus verified by quantitative PCR (Q-PCR) the HRGinduced expression of these genes in both the parental T47D cells and in the ErbB2-overexpressing SKBr3 breast carcinoma cell line (Table 1 and Supplementary Figure S3 ). We focused our attention to the nine genes that were induced more than twofold in both cell lines.
Identification of soluble ST2 as a target of ErbB2-mediating migration
The contribution of the candidate genes to HRGinduced cell migration was studied by small interfering RNA (siRNA) targeting ( Figure 3a ). Of note, we observed that ErbB2 overexpression was sufficient to confer proliferative, but not migratory, properties so that addition of HRG was required to induce migration of both ErbB2-overexpressing (SKBr3) and non-overexpressing (T47D) cells. We only studied genes for which we achieved an mRNA extinction above 80% in both T47D and SKBr3 cells, as analyzed by Q-PCR (Supplementary Figure S4) . This excluded DUSP6, FGFBP1 and SYTL2. Depletion of IL1RL1/ST2 or F2RL1 strongly reduced HRG-induced migration of both T47D and SKBr3 cells (Figure 3a) . The F2RL1 gene encodes the protease-activated receptor-2 (PAR2) protein, whose role in migration of breast cancer cells is documented (Su et al., 2009) . The IL1RL1/ST2 protein, which belongs to the IL-1R gene family, is an effector of T-helper 2 responses (Meisel et al., 2001; Schmitz et al., 2005; Kakkar and Lee, 2008) , but widespread expression of variant 2 suggests a role in different cellular functions.
We further studied the contribution of ST2 to ErbB2-dependent migration. A distinct ST2 siRNA led to similar inhibition of ErbB2-driven migration (Figure 3b ), confirming that inhibition was actually due to ST2 targeting. The IL1RL1/ST2 gene encodes two major mRNAs (Bergers et al., 1994; Rossler et al., 1995) . Variant 1 encodes a membrane-bound ST2 protein (ST2L). Variant 2, which encodes a soluble protein (sST2) nearly identical to the extracellular region of ST2L, may act as an antagonistic decoy receptor Figure 2 Identification of ErbB2 transcriptional targets. Neu and NYPD cells were exposed to 1 nM HRG for 0, 2, 4, 6 or 24 h. RNA expression profiling was analyzed using DNA microarrays. (a) Hierarchical clustering of Neu and NYPD cells across the migration kinetics based on mRNA expression levels of 18 503 probe sets retained after filtering (left panel). Before clustering, filtered data were log 2 -transformed and submitted to the cluster program (Eisen et al., 1998) using the median-centered data on genes, Pearson correlation as similarity metrics and centroid linkage clustering. Results are displayed using Java TreeView program (v1.1.3, http://jtreeview.sourceforge.net/). Each row represents a gene and each column represents an experimental point. The expression level of each gene in a single experiment point is relative to its median abundance across all experimental points. Red and green indicate expression levels, respectively, above and below the median. The magnitude of deviation from the median is represented by the color saturation. The dendrogram represents overall similarities in gene expression profile and is zoomed (right panel). (b) mRNA expression profile of the MMP-1 gene in Neu and NYPD cells obtained from the microarray analysis. Mean value from two independent clones. a.u., arbitrary units.
sST2 in breast tumor cell motility and metastasis J Gillibert-Duplantier et al (Hayakawa et al., 2007) . A third variant, ST2V, has been described (Tominaga et al., 1999) , but its tissue distribution and function remain unclear. We determined the expression of each ST2 mRNA variant in T47D and SKBr3 cells by Q-PCR (Figure 3c ). The ST2L variant was almost undetectable in T47D and SKBr3 cells. The sST2 variant was strongly induced upon HRG stimulation in both cell lines. ST2V was not detectable by Q-PCR analysis (data not shown). These results suggested that ErbB2 activity led to increased sST2 expression and that sST2 was involved in ErbB2-driven cell motility.
sST2 is secreted by and binds to breast carcinoma cells We analyzed sST2 protein production and secretion by enzyme-linked immunosorbent assay (ELISA). SKBr3 cells produced low amounts of sST2; HRG stimulation increased sST2 expression and secretion ( Figure 4a ). Similar results were obtained with T47D cells although the amount of secreted sST2 was lower (data not shown). sST2 secretion appears important for ErbB2-driven cell migration as an ST2-blocking antibody reduced HRG-induced migration of both cell lines ( Figure 4b ). As ST2L expression was barely detectable in these cells, sST2 was unlikely to act as a decoy receptor. Thus, our result suggested that secreted sST2 had pro-migratory activity via a specific binding site on the cell surface. This suggestion was supported by flow cytometry analysis, which showed binding of rhST2-Fc, a chimera composed of the extracellular domain of ST2 fused to the human Fc IgG fragment, to the surface of T47D and SKBr3 cells (Figure 4c ). Nectin3-Fc, which binds to the ubiquitously expressed Nectin1, and CTLA4-Fc, which interacts with B lymphocyte CD80/ CD86 (Fabre et al., 2002) , served as positive and negative controls, respectively. ST2-Fc did not interact with Raji cells, as previously described (Gayle et al., 1996) . Binding increased with rhST2 concentrations and was saturable (Supplementary Figure S5) . We then evaluated whether addition of sST2 could stimulate breast cancer cell motility. Adding rhST2 to T47D cells did not change the level of basal migration but enhanced migration induced by HRG (Figure 4d ). However, rhST2 was ineffective in enhancing HRGinduced SKBr3 cell migration (data not shown); the divergent responses of the two cell lines remain to be explained. Finally, addition of rhST2 compensated siRNA-mediated depletion of ST2 to restore ErbB2- 
Zinc finger protein 365 þ À T47D and SKBr3 cells were exposed to 1 nM HRG for 0 to 24 h before evaluation of mRNA expression levels by quantitative PCR (Q-PCR).
a Genes whose expression was more than twofold above control at any time point are listed as induced.
b
Genes that were not induced in both cell lines and were not further studied. Expression profile for each gene is shown in Supplementary  Figure S3 . sST2 in breast tumor cell motility and metastasis J Gillibert-Duplantier et al dependent cell motility (Figure 4d ), confirming that ST2 functioned as an extracellular ligand to mediate ErbB2-driven motility.
sST2 in breast cancer patients Our data show that breast tumor cell lines are induced to secrete sST2 in response to ErbB2 activation and that secretion of sST2 is associated with increased motility. We wanted to determine whether sST2 was also secreted by freshly collected tumor cells. Total cells were isolated from freshly resected primary tumors and from metastatic pleural effusions or ascitic fluids from breast cancer patients, and equivalent numbers of cells were grown in vitro for 24 h, before analysis of secreted sST2 content in culture supernatants. Cells isolated from tumors secreted detectable levels of sST2 (Figure 5a ). Interestingly, sST2 levels were eightfold higher in cell supernatants from metastatic samples than in cell supernatants from primary tumors. While cells from pleural effusions secreted levels of sST2 comparable to primary tumors, cell supernatants from peritoneal fluids contained 14-fold more sST2 than cell supernatants from primary tumors (Figure 5a ). Thus, cells from metastatic samples secrete much higher levels of sST2 than cells from primary breast tumors. However, cells might have been induced to secrete sST2 upon disruption of the tumors or upon growth in culture. We quantified sST2 directly in pleural and peritoneal fluids (Figure 5b ). sST2 was detectable in both fluids, but was present at higher levels in peritoneal fluids similarly to what was observed in cell culture supernatants. Interestingly, when samples from the same patients were available, we observed a correlation between sST2 levels in pleural/peritoneal effusions and tumor cell supernatants (data not shown).
Several studies have shown high levels of sST2 in serum from various diseases (Kakkar and Lee, 2008) . We analyzed ST2 levels in serum from healthy donors, patients with primary breast tumors and patients with breast tumor metastasis. Levels of sST2 were higher in patients with metastatic disease than in non-metastatic patients with primary tumors or healthy donors (Figure 5c ). Actually, Effect of an anti-ST2-blocking antibody on cell migration. Cells were allowed to migrate in response to HRG for 24 h. Anti-ST2-blocking antibody (5 mg/ml) or control IgG was added to the culture medium 6 h after the beginning of migration. Results are from three independent experiments done in triplicate and are shown as median ± (Q1; Q3). Migration in the presence of control IgG was set at 100%. sST2 in breast tumor cell motility and metastasis J Gillibert-Duplantier et al 36% of patients with metastatic tumors, but only 2% of patients with primary tumors, had sST2 levels above 100 pg/ml (Figure 5c ). Thus, high levels of sST2 in serum are associated with a metastatic disease.
Discussion
Overexpression of ErbB2 in breast tumors is associated with aggressiveness of disease. Activation of ErbB2 favors tumor growth, but also cell motility and metastasis. Most studies of cell motility focused on posttranslational events, yet cell motility is also regulated at the transcriptional level (Kustikova et al., 1998; Jauliac et al., 2002; Vial et al., 2003; Michl et al., 2005) . We aimed at identifying genes involved in ErbB2-dependent cell motility and revealed a group of genes that are differentially expressed in migrating cells. Among these, we characterized sST2 as a protein that is expressed in response to ErbB2 activation and contributes to ErbB2-driven motility. Moreover, sST2 is secreted by metastatic breast cancer cells and found at high levels in the serum of patients with metastatic tumors. Among the genes most highly regulated by ErbB2, we found the MMPs MMP1 and MMP10 which have been involved previously in cell migration (Dufour et al., 2008; Ho et al., 2009) . But MMP1 and MMP10 did not contribute to cell motility in our experimental system. However, considering that they are strongly induced upon ErbB2 activation, they are likely to contribute to tumor invasion in a physiological context. Other ErbB2 target genes belong to various functional categories that are linked to cell motility. However, among the genes we tested, only F2RL1/PAR2 and sST2 contributed to ErbB2-driven migration. PAR2 activation promotes breast cancer cell migration (Morris et al., 2006; Su et al., 2009) . Interestingly, this function could be mediated by transactivation of EGFR/ErbB2 (Caruso et al., 2006; Jarry et al., 2007) , suggesting the possibility of a positive feedback loop. Future studies will be required to establish the contribution of PAR2 to ErbB2-driven breast cancer cell motility.
ST2/IL1RL1 is a transmembrane protein that belongs to the family of the interleukin-1 receptor and was identified as a receptor for interleukin-33. ST2 contributes to inflammatory processes, especially those involving mast cells or Th2 T-cells, but also to cardiovascular pathophysiology (Kakkar and Lee, 2008) . sST2 arises from differential splicing leading to different promoter usage and is characterized by the absence of the transmembrane and cytoplasmic domains. sST2 has been involved in the attenuation of ST2L-dependent processes, most likely because of its role as a decoy receptor (Hayakawa et al., 2007; Sanada et al., 2007) . In contrast, our data suggest that sST2 has a stimulatory action on ErbB2-dependent cell motility. It is unlikely that sST2 functions via inhibition of ST2L, as we found little or no ST2L expression in our cell lines. Moreover, we found that sST2 is capable of triggering intracellular signaling, as it induced transient activation of the Ras/mitogen-activated protein kinase pathway in breast cancer cell lines (Supplementary Figure S6) . Thus, we postulate that sST2 associates to a yet undefined membrane receptor to stimulate signaling that, in cooperation with ErbB2 activity, promotes cell motility. A report suggested that transmembrane emp24 domain-containing protein 1 (TMED1) was a putative Figure 5 High sST2 is associated with metastasis. (a) Cells obtained from primary breast tumors (n ¼ 21) or from metastatic patients pleural effusions (n ¼ 9) or ascites (n ¼ 10) were grown for 24 h before collection of cell culture supernatants and analysis of ST2 content by ELISA. Graph shows individual samples (dots) and mean concentrations (dash). **Po10
À4
; ns, not significant (Student's t-test). (b) Concentration of sST2 was measured directly in pleural effusions (n ¼ 17) and ascites (n ¼ 17), and represented as in a. **Po0.005. (c) Elevated concentrations of serum sST2 in metastatic breast cancer patients. sST2 was measured by ELISA in serum from healthy donors and patients with localized (primary) or metastatic breast cancer. Dashed line indicates 0.100 ng/ml. *Po0.05; **Po0.005. sST2 in breast tumor cell motility and metastasis J Gillibert-Duplantier et al ST2-binding protein on A172 glioblastoma cell membranes (Gayle et al., 1996) , but this observation was not confirmed in later studies. It will be critical to identify sST2 receptor to unravel its functions and mechanism of action.
While our data describe an autocrine sST2 function, sST2 might also impact tumor cells in a paracrine manner, as it is also expressed by fibroblasts (Tominaga, 1989; Werenskiold et al., 1989; Rossler et al., 1995) . In addition, sST2 might also affect local or distant immune response via downregulation of ST2L function on helper T cells. Thus, sST2 expression could impact tumors at multiple levels that could only be studied in more complex animal models.
Metastatic breast tumor cells collected from ascitic fluid secreted high levels of sST2 relative to primary tumors. Although carcinoma cells compose the majority of the tumors, we cannot exclude that sST2 was secreted by fibroblasts or infiltrating immune cells. Increased sST2 might simply reflect an increase of the stromal compartment. However, a preliminary analysis did not reveal more stromal cells in the ascites-derived cell cultures nor increased inflammation-associated cytokines, such as TNFa and PGE2, in the ascites-derived cell supernatants (VS and NB-V, unpublished observations). Cell sorting before collection of the supernatants is required to determine the source of sST2. Surprisingly, metastatic cells from pleural effusion did not secrete increased levels of sST2. We do not know yet whether this is a reflection of different intrinsic properties of metastatic cells from ascites fluids and pleural effusions, or whether it is a consequence of distinct cellular environments.
Serum sST2 has emerged as a marker for several types of diseases, including cardiopathy and asthma (Oshikawa et al., 2001; Tajima et al., 2003; Brunner et al., 2004; Kakkar and Lee, 2008) . A fraction of our patients with metastatic breast cancer showed elevated levels of sST2. As sST2 is also increased in other pathologies, one cannot exclude that elevated sST2 might be the consequence of processes unrelated to metastatic progression. However, high sST2 was almost never found in non-metastatic breast cancer patients. Because of the limited number of confirmed ErbB2-amplified patients among the cohort of metastatic patients (7 out of 50, Supplementary Table S2), we could not establish whether high sST2 correlated with ErbB2 overexpression. Interestingly, we observed that many ErbB2-negative patients (10 out of 27) showed high sST2 serum levels. Thus, we postulate that in these patients expressing low levels of ErbB2, sST2 was induced by ligand-dependent activation of ErbB2 or by factors others than ErbB2. Along that line, it is worth mentioning that sST2 was originally identified as a serum and oncogene-induced gene in fibroblasts Tominaga, 1989; Werenskiold et al., 1989) and was described, more recently, as part of an H-Ras oncogenic signature in human mammary epithelial cells (Bild et al., 2006) .
Preliminary transcriptomic analysis of breast cancer patient tumors and cell lines did not show overexpression of sST2 mRNA in metastatic tumors, suggesting that sST2 expression in patients should be investigated at the protein level. In the future, it would be of the highest interest to determine whether high sST2 in metastatic patients correlates with specific clinical parameters and could serve as a serum marker of disease severity or progression.
Materials and methods
Reagents
Cycloheximide, 5,6-dicholorobenzimidazole 1-b-D ribofuranoside (DRB) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) were from Sigma-Aldrich (SaintQuentin-Fallavier, France).
Cell culture and transfection T47D and SKBr3 breast carcinoma cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Cergy Pontoise, France) supplemented with 10% fetal calf serum (Eurobio, Courtaboeuf, France), 1 mM sodium pyruvate and penicillin/streptomycin (Invitrogen). T47D-derived cells expressing Neu or mutant Neu lacking the five major autophosphorylation sites (NYPD cells) were obtained as described (Marone et al., 2004) . All experiments were performed in two independently raised Neu-expressing (Neu1 and Neu2) and NYPD-expressing (NYPD1 and NYPD2) cell lines. T47D and SKBr3 cells were transiently transfected with specific siRNAs (listed in Supplementary Table S1) using the Lonza (LevalloisPerret, France) nucleofection technology.
Flow cytometry
To measure sST2 binding to the cell surface, sub-confluent cells were collected in phosphate-buffered saline/ethylenediaminetetraacetic acid, incubated for 1 h at 4 1C with recombinant chimera protein sST2-Fc (R&D Systems, Lille, France), then washed with phosphate-buffered saline/0.1% bovine serum albumin and incubated with a phycoerythrin-coupled goat anti-human antibody for an additional hour before analysis by flow cytometry with a FACS Scan cytometer (Becton-Dickinson, Le Pont-de-Claix, France). Nectin-3-Fc chimera and CTLA4-Fc chimera (kindly provided by M Lopez, CRCM, Marseille, France) were used as positive and negative controls, respectively.
Proliferation and migration assay
To measure cell proliferation/survival, 5 Â 10 4 /ml cells were seeded on 6-well plates for 24 h, before serum starvation for another 24 h and addition of 1 nM HRG-b1 (R&D Systems) for 0, 1 or 4 days. Relative cell number was evaluated both by flow cytometry and MTT assay, and expressed as proliferation index (ratio of HRG-treated cells over untreated cells). Cell migration was tested using rat-tail collagen I (Roche Diagnostics, Meylan, France)-coated 8 mm-pore Transwell chambers (Corning), using HRG-b1 or rhST2-Fc (R&D Systems) as chemoattractant, as described (Marone et al., 2004) . When indicated, anti-ST2 antibody (R&D Systems) was added 6 h after HRG-b1.
Microarray analysis
Neu1, Neu2, NYPD1 and NYPD2 cells were grown in 24-mm Transwell chambers with HRG-b1 for 0 (H0), 2 (H2), 4 (H4), 6 (H6) and 24 (H24) h. Total RNA from the 20 samples (two samples per cell line for each time point) was isolated using the sST2 in breast tumor cell motility and metastasis J Gillibert-Duplantier et al
Qiagen RNeasy Mini Kit. RNA integrity was controlled by micro-analysis (Agilent, Massy, France). RNA expression profiling was done using Human Genome U133 Plus 2.0 microarrays (Affymetrix, High Wycombe, UK). cRNA preparations, hybridizations, washes and detection were done as described (Charafe-Jauffret et al., 2006) . Expression data were analyzed by Robust Multichip Average method in R using Bioconductor and associated package (Irizarry et al., 2003 
Q-PCR analysis
Total RNA was isolated using the Qiagen RNeasy Mini Kit in the presence of RNase-free DNase I. A total of 2 mg of total RNA was reverse-transcribed with Qiagen Superscript II using random hexamers. Diluted RT products and specific primers were mixed with SYBR Green PCR Master Mix, and mRNA relative abundance was analyzed with the 7900-HT Fast RealTime PCR system from Applied Biosystems (Courtaboeuf, France). Sequence of primers is available upon request.
Dosage of soluble ST2
Cell lysates were prepared as mentioned above. Conditioned medium of T47D and SKBr3 cells was centrifuged 5 min at 2000 r.p.m. and 15 min at 14 000 r.p.m. before analysis. Cell lysates and conditioned medium were assayed for soluble ST2 using the R&D Systems human IL-1R4/ST2 DuoSet ELISA and Becton-Dickinson OptEIA TMB substrate reagent. Fresh primary tumor samples and metastatic pleural and peritoneal effusions from breast cancer patients were obtained from the Centre Le´on Be´rard (Lyon, France) tissue bank after patient informed consent and histological confirmation of diagnosis. For preparation of breast tumor-derived supernatants, singlecell suspensions from primary and metastatic breast tumors were seeded in supplemented RPMI 1640 medium at 1.5 Â 10
